UCL University College London Eprints
UCL Eprints collects the work of UCL researchers and makes it freely available over the web, helping the worldwide scholarly community to discover UCL research. Institutional repositories like UCL Eprints complement the traditional academic publishing and scholarly communications processes. They raise the visibility of research and help to maximise its impact. UCL researchers are encouraged to deposit a copy of each journal article, conference paper, working paper, and any other research output, in the UCL Eprints at the earliest opportunity, ensuring that their research reaches as wide an audience as possible.
Mostrando recursos 141 - 160 de 344,855
Multi-modal measurement of the myelin-to-axon diameter g-ratio in preterm-born neonates and adult controls. - Melbourne, A; Eaton-Rosen, Z; De Vita, E; Bainbridge, A; Cardoso, MJ; Price, D; Cady, E; Kendall, GS; Robertson, NJ; Marlow, N; Ourselin, S
Infants born prematurely are at increased risk of adverse functional outcome. The measurement of white matter tissue composition and structure can help predict functional performance and this motivates the search for new multi-modal imaging biomarkers. In this work we develop a novel combined biomarker from diffusion MRI and multi-component T2 relaxation measurements in a group of infants born very preterm and scanned between 30 and 40 weeks equivalent gestational age. We also investigate this biomarker on a group of seven adult controls, using a multi-modal joint model-fitting strategy. The proposed emergent biomarker is tentatively related to axonal energetic efficiency (in...
Longitudinal measurement of the developing thalamus in the preterm brain using multi-modal MRI. - Eaton-Rosen, Z; Melbourne, A; Orasanu, E; Modat, M; Cardoso, MJ; Bainbridge, A; Kendall, GS; Robertson, NJ; Marlow, N; Ourselin, S
Preterm birth is a significant public health concern. For infants born very preterm (≤ 32 weeks completed gestation), there is a high instance of developmental disability. Due to the heterogeneity of patient outcomes, it is important to investigate early markers of future ability to provide effective and targeted intervention. As a neuronal relay centre, the thalamus is critical for effective cognitive function and, thus, development of white matter connections between the thalamus and cortex is vital. By non-invasively examining the state of the thalamus we can monitor development in the preterm period. To track the development we develop a novel...
Distinct neural responses to conscious versus unconscious monetary reward cues - Bijleveld, E; Custers, R; Van der Stigchel, S; Aarts, H; Pas, P; Vink, M
Human reward pursuit is often assumed to involve conscious processing of reward information. However, recent research revealed that reward cues enhance cognitive performance even when perceived without awareness. Building on this discovery, the present functional MRI study tested two hypotheses using a rewarded mental-rotation task. First, we examined whether subliminal rewards engage the ventral striatum (VS), an area implicated in reward anticipation. Second, we examined differences in neural responses to supraliminal versus subliminal rewards. Results indicated that supraliminal, but not subliminal, high-value reward cues engaged brain areas involved in reward processing (VS) and task performance (supplementary motor area, motor cortex,...
Influence of positive subliminal and supraliminal affective cues on goal pursuit in schizophrenia. - Chaillou, AC; Giersch, A; Bonnefond, A; Custers, R; Capa, RL
Goal pursuit is known to be impaired in schizophrenia, but nothing much is known in these patients about unconscious affective processes underlying goal pursuit. Evidence suggests that in healthy individuals positive subliminal cues are taken as a signal that goal pursuit is easy and therefore reduce the effort that is mobilized for goal attainment. Patients with schizophrenia and healthy controls were instructed that a long run of successive correct responses in a visual attention task would entitle them to a reward (the goal to attain). Affective pictures were displayed supraliminally or subliminally during each run and electrophysiological activity was recorded....
Bortezomib, low-dose intravenous melphalan, and dexamethasone for patients with relapsed multiple myeloma - Popat, R; Oakervee, H; Williams, C; Cook, M; Craddock, C; Basu, S; Singer, C; Harding, S; Foot, N; Hallam, S; Odeh, L; Joel, S; Cavenagh, J
This multicenter phase I/II study investigated the maximum tolerated dose (MTD), safety, and efficacy of low dose intravenous (IV) melphalan in combination with bortezomib for patients with relapsed multiple myeloma (MM). Patients received bortezomib 1.3 mg/m(2) on days 1, 4, 8, and 11 and escalating doses of IV melphalan (2.5-10.0 mg/m(2)) on day 2 of a 28-day cycle for a maximum of eight cycles. Dexamethasone 20 mg was added for progressive or stable disease. Fifty-three patients were enrolled. The MTD was defined at melphalan 7.5 mg/m(2) and bortezomib 1.3 mg/m(2). The overall response rate (ORR) was 68% (23% complete or...
Re-transplantation after bortezomib-based therapy - Morris, C; Cook, G; Streetly, M; Kettle, P; Drake, M; Quinn, M; Cavet, J; Tighe, J; Kazmi, M; Ashcroft, J; Cook, M; Snowden, J; Olujohungbe, A; Marshall, S; Conn, J; Oakervee, H; Popat, R; Cavenagh, J
Bortezomib, doxorubicin and dexamethasone (PAD) front-line treatment of multiple myeloma: updated results after long-term follow-up - Popat, R; Oakervee, HE; Hallam, S; Curry, N; Odeh, L; Foot, N; Esseltine, DL; Drake, M; Morris, C; Cavenagh, JD
Bortezomib, doxorubicin and dexamethasone (PAD) was evaluated as induction before stem cell transplantation in newly diagnosed multiple myeloma (MM) patients, using bortezomib 1.3 mg/m(2) (PAD1, N = 21) or 1.0 mg/m(2) (PAD2, N = 20). Complete/very good partial response rates with PAD1/PAD2 were 62%/42% postinduction and 81%/53% post-transplant. Progression-free survival (29 vs. 24 months), time to re-treatment (36 vs. 29 months) and overall survival (1 year: 100% vs. 95%; 2 years: 95% vs. 73%) were statistically similar but favoured PAD1 versus PAD2. Toxicity was lower in PAD2; bortezomib dose reduction may help manage toxicities while retaining efficacy. PAD is highly...
Use of bortezomib as induction therapy prior to stem cell transplantation in frontline treatment of multiple myeloma: Impact on stem cell harvesting and engraftment - Oakervee, H; Popat, R; Cavenagh, JD
High-dose melphalan therapy with peripheral blood stem cell ( PBSC) transplantation is a standard treatment for younger patients with untreated multiple myeloma that results in high overall and complete response ( CR) rates, and improved event-free and overall survival compared with standard chemotherapy alone. Induction therapy serves to reduce tumor burden prior to stem cell mobilization and thus must not adversely impact stem cell mobilization and harvesting, or engraftment following high dose therapy plus autologous stem cell transplantation. Bortezomib, an approved agent for the treatment of multiple myeloma patients who have received at least one prior therapy, is also being...